-
公开(公告)号：US20230312537A1
公开(公告)日：2023-10-05
申请号：US18173573
申请日：2023-02-23
发明人： Melissa Fleury , Adam D. Hughes
IPC分类号： C07D405/12 , A61K31/415 , A61K31/4192 , A61K31/42 , A61K31/421 , A61K45/06 , C07D231/14 , C07D231/20 , C07D249/04 , C07D261/18 , C07D263/38
CPC分类号： C07D405/12 , A61K31/415 , A61K31/4192 , A61K31/42 , A61K31/421 , A61K45/06 , C07D231/14 , C07D231/20 , C07D249/04 , C07D261/18 , C07D263/38
摘要： In one aspect, the invention relates to compounds having the formula:
where X, Ra, Rb, R2, and R7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.-
公开(公告)号：US20220380325A1
公开(公告)日：2022-12-01
申请号：US17363534
申请日：2021-06-30
IPC分类号： C07D263/46 , A61P35/00 , C07D271/113 , C07D261/08 , C07D263/48 , C07D231/38 , C07D239/42 , C07D233/74 , C07D277/36 , C07D277/42 , C07D277/56 , C07D307/64 , C07D241/20 , C07D263/38 , C07D233/84 , C07D233/88 , C07D233/80 , C07D233/76
摘要： The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer including prostate cancer.
-
公开(公告)号：US20210340114A1
公开(公告)日：2021-11-04
申请号：US17226854
申请日：2021-04-09
IPC分类号： C07D263/46 , A61K31/4418 , A61P27/02 , A61K31/421 , C07D231/22 , C07D239/34 , A61K31/505 , C07D263/38 , C07D213/70 , C07D213/65 , C07D231/12 , A61K31/415 , C07K14/47 , C12N15/09
摘要： Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.
A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.-
公开(公告)号：US20210130301A1
公开(公告)日：2021-05-06
申请号：US17142586
申请日：2021-01-06
发明人： Karen Annette DUGGAN
IPC分类号： C07D239/26 , A61P11/00 , C07C39/15 , C07C215/54 , C07C233/11 , C07D207/408 , C07D213/56 , C07D237/08 , C07D261/14 , C07D263/44 , C07D277/30 , C07D401/10 , C07D403/10 , C07D333/24 , C07C233/07 , C07D231/56 , C07D235/26 , C07D235/06 , C07C59/52 , C07C275/42 , C07D213/73 , C07D277/68 , A61P11/06 , C07D231/12 , C07C211/29 , C07D207/38 , C07C255/00 , C07C271/28 , C07C217/48 , C07C261/04 , C07D241/12 , C07D309/10 , C07D233/78 , C07D261/08 , C07D209/48 , C07C237/20 , C07D207/327 , C07C237/22 , C07D307/54 , C07D249/18 , C07D209/34 , C07D263/38 , C07C307/10 , C07D207/26 , C07D207/444 , C07C235/34 , C07C311/03 , C07C311/08 , C07C239/20 , C07C235/78 , C07D209/18 , C07D263/58 , C07D215/14 , C07D207/40
摘要： The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.
-
公开(公告)号：US10544111B2
公开(公告)日：2020-01-28
申请号：US16230634
申请日：2018-12-21
IPC分类号： C07D263/46 , A61K31/415 , A61K31/421 , A61K31/4418 , A61K31/505 , C07D231/12 , C07D231/22 , C07D239/34 , C07D263/38 , C07D213/65 , A61P27/02 , C07D213/70 , C07K14/47 , C12N15/09
摘要： Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.
-
公开(公告)号：US20200017436A1
公开(公告)日：2020-01-16
申请号：US16392920
申请日：2019-04-24
发明人： Melissa Fleury , Adam D. Hughes
IPC分类号： C07C229/22 , C07D249/18 , A61K31/4192 , A61K45/06 , C07D231/20 , A61K31/415 , C07D405/12 , A61K31/4155 , A61K31/4439 , C07D401/04 , C07D405/14 , C07D231/14 , C07D261/18 , A61K31/42 , C07D249/04 , C07D249/12 , A61K31/4196 , C07D257/04 , A61K31/41 , A61K31/675 , C07F9/6503 , C07D231/18 , C07D253/08 , C07C271/22 , C07D207/26 , C07D263/38
摘要： In one aspect, the invention relates to compounds having the formula XII: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
-
7.发明申请公开(公告)号：US20190047977A1
公开(公告)日：2019-02-14
申请号：US15948821
申请日：2018-04-09
IPC分类号： C07D327/06 , C07D319/16 , C07D311/02 , C07D311/04 , C07D263/58 , C07D235/26 , C07D215/06 , C07D307/79 , C07D211/72 , C07D263/38 , C07D233/70 , C07D319/18 , C07D317/62 , C07D317/46 , C07D317/50
摘要： Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
-
公开(公告)号：US20180327350A1
公开(公告)日：2018-11-15
申请号：US15843427
申请日：2017-12-15
发明人： Melissa Fleury , Adam D. Hughes
IPC分类号： C07C229/22 , C07D249/04 , C07D207/26 , C07D401/04 , C07D405/12 , C07D249/18 , C07F9/6503 , A61K31/675 , A61K31/41 , A61K31/4196 , A61K31/42 , A61K31/4439 , A61K31/4155 , A61K31/415 , A61K45/06 , A61K31/4192 , C07D257/04 , C07D249/12 , C07D231/14 , C07D405/14 , C07D231/20 , C07D253/08 , C07D231/18 , C07C271/22 , C07D263/38 , C07D261/18
CPC分类号： C07C229/22 , A61K31/41 , A61K31/415 , A61K31/4155 , A61K31/4192 , A61K31/4196 , A61K31/42 , A61K31/4439 , A61K31/675 , A61K45/06 , C07C271/22 , C07D207/26 , C07D231/14 , C07D231/18 , C07D231/20 , C07D249/04 , C07D249/12 , C07D249/18 , C07D253/08 , C07D257/04 , C07D261/18 , C07D263/38 , C07D401/04 , C07D405/12 , C07D405/14 , C07F9/65031
摘要： In one aspect, the invention relates to compounds having the formula XII: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
-
公开(公告)号：US20180237423A1
公开(公告)日：2018-08-23
申请号：US15841749
申请日：2017-12-14
发明人： Melissa Fleury , Adam D. Hughes
IPC分类号： C07D405/12 , A61K31/4192 , C07D231/20 , C07D231/14 , C07D249/04 , C07D261/18 , C07D263/38 , A61K31/415 , A61K31/42 , A61K31/421 , A61K45/06
CPC分类号： C07D405/12 , A61K31/415 , A61K31/4192 , A61K31/42 , A61K31/421 , A61K45/06 , C07D231/14 , C07D231/20 , C07D249/04 , C07D261/18 , C07D263/38
摘要： In one aspect, the invention relates to compounds having the formula: where X, Ra, Rb, R2, and R7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
-
公开(公告)号：US20180072682A1
公开(公告)日：2018-03-15
申请号：US15557762
申请日：2016-03-18
发明人： KAREN ANNETTE DUGGAN
IPC分类号： C07D233/78 , C07C215/54 , C07D207/26 , C07D207/38 , C07D233/96 , C07D261/14 , C07D263/38 , C07C239/20 , C07D263/44 , C07D209/48 , C07C59/54 , C07C39/12
CPC分类号： C07D233/78 , C07C39/12 , C07C39/15 , C07C47/575 , C07C59/52 , C07C59/54 , C07C215/48 , C07C215/54 , C07C239/20 , C07D207/26 , C07D207/267 , C07D207/36 , C07D207/38 , C07D207/408 , C07D207/448 , C07D209/48 , C07D233/96 , C07D261/14 , C07D263/38 , C07D263/44
摘要： The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of fibrosis and fibrosis-related conditions.
-
-
-
-
-
-
-
-
-
搜索结果
199 条记录 (耗时 0.039 秒)
